latest development

London (UK) and Rehovot (Israel) July 5th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).

Vidac Pharma was invited to organize a Round Table discussion on its new paradigm for Drug Discovery: the “Toposteric effect” at the Health Tech Innovation Days conference in Paris, October 24-25, 2023.

The Company will bring together specialists from Europe and Israel to discuss the implications of this new concept which already gave rise to its VDA 1102 drug already proven effective in Phase 2 in the AK-SCC spectrum as well as new developments from other groups both in cancer and in neurodegenerative diseases.

The Round Table discussion will be open to all participants of the conference. “It is a big honor and recognition to be chosen to run one of the very few Round Tables of the Conference” declared Dr Max Herzberg Chairman & CEO of the Company, “Our new concept opens the route to Drug developments with potentially lower side effects a very important factor for patient’s wellbeing and compliance”

Rehovot (Israel) and London (UK)

About Vidac Pharma:
Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.

The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
+972 (0)779300647